


Toxys Revenue
Research Services • Oegstgeest, South Holland, Netherlands • 21-50 Employees
Toxys revenue & valuation
| Annual revenue | $6,200,000 |
| Revenue per employee | $173,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Research Services industry and current estimated revenues | $19,900,000 |
| Total funding | $2,200,000 |
Key Contacts at Toxys
Johan Sebregts
Member Board Of Directors
Elias Halkes-Wellstead
Director Of Sales And Business Development
José Manuel Horcas Nieto
Director Of Developmental Toxicity
Sabine Hartvelt
Study Director
Mathyn Rijkers
Study Director
Company overview
| Headquarters | De Limes 7, Oegstgeest, 2342 DH, NL |
| Phone number | +31713322470 |
| Website | |
| NAICS | 5417 |
| SIC | 873 |
| Keywords | Stem Cells, Dna Damage Response, Bac Technologies, Genotoxicity Testing, Mammalian Reporter Assays, Mechanism-Based Toxicology |
| Founded | 2014 |
| Employees | 21-50 |
| Socials |
Toxys Email Formats
Toxys uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@toxys.com), used 57.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@toxys.com | 57.7% |
{first initial}.{last name} | j.doe@toxys.com | 42.3% |
About Toxys
Toxys is global leading expert that develops and offers a broad spectrum of unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. We are experts in the fields of genotoxicity, developmental toxicology and mechanistic toxicity testing. We develop assays with the focus on understanding the mode-of-action of toxic compounds. Our ToxTracker® assay accurately identifies genotoxic compounds, ReproTracker® detects developmental toxicity and the ToxProfiler™ assay provides a broad toxicity profile of compounds. Our unique assays provide relevant information to avoid compounds failing at a late stage of development due to unforeseen toxicity. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in drug/compound development, thereby contributing to the development of better medicines and products and to reduce animal testing. Every novel chemical compound that is developed by pharmaceutical, chemical, cosmetics or food companies has to be rigorously tested for human health hazards before being considered safe for marketing. Current in vitro toxicity tests, which are an essential part of compound risk assessment, often suffer from a low predictive value and lack the possibility to provide insight into the mode-of-action of toxic compounds. To address these unmet needs, Toxys offers a diverse portfolio of in vitro assays that provide mode-of-action information on toxic compounds and provide information relevant to human health. The assays are used for early compound screening, follow-up testing and mode-of-action assessment, potency ranking and chemical read-across and are particularly useful in weight-of-evidence (WoE) and adverse outcome pathway (AOP) approaches for chemical safety assessment. Toxys is internationally recognised for its scientific expertise, high-quality results and responsiveness.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Toxys has 9 employees across 5 departments.
Departments
Number of employees
Toxys Tech Stack
Discover the technologies and tools that power Toxys's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Video players
Security
Hosting
JavaScript libraries
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
JavaScript graphics
Frequently asked questions
4.8
40,000 users



